Alice Chen, MD, FACP Investigational Drug Branch, CTEP, DCTD National Cancer Institute CTCAE Version 4.

Slides:

Advertisements

Similar presentations

HL7 Version 3 Laboratory Result-based Adverse Event Assessment Message Specifications RCRIM Technical Meeting September 18, 2007 Jennifer Neat Project.

Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB

Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010

Safety Reporting IN Clinical Trials

ADVERSE EVENT REPORTING

Adverse Events: An Update

Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Pharmacovigilance Dr. Muiris Dowling,

SAE Reconciliation How to handle ‘a waterfall’ of SAEs?

©2013 MFMER | slide-1 Building A Knowledge Base of Severe Adverse Drug Events Based On AERS Reporting Data Using Semantic Web Technologies Guoqian Jiang,

Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs

Capturing and Reporting Adverse Events in Clinical Research

Director, Investigator Support & Integration Services, OCTRI

Arizona Department of Health Services and Rural Health Office Webinar Series: Issues in Rural Health Planning Community Health Assessment Overview Howard.

Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 1 Overview of Nursing Process, Clinical Reasoning, and Nursing Practice.

FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.

SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.

SESIH Redesign Update Older Persons and Chronic Care Project Paul Preobrajensky Manager Redesign Program 19 September 2007.

Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

Month, day, year Reporting Adverse Events What, When, How? Cynthia Gross Professor, College of Pharmacy and School of Nursing The MN Center for Health.

CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.

DHHS / FDA / CDRH 1 Circulatory Support Devices Panel Tuesday, September 11, 2001 CoSeal® Surgical Sealant P

Adverse Event Reporting.

Development and Approval of Drugs and Devices EPI260 Lecture 9 May 23, 2012 Richard Chin, M.D.

Clinical Risk Unit University College London International Perspectives Feedback from the review board Charles Vincent Clinical Risk Unit University College.

HL7 RCRIM Meeting: 9 January 2007 CDISC-RCRIM Vocab Update: Related CDISC Terminology Projects Bron Kisler, CDISC Terminology Program Director

AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.

Semantic MediaWiki in Action: CTCAE Revision Project Traci St. Martin, Ann Setser and Lewis Frey Architecture/VCDE Face-to-Face Meeting Northwestern University,

EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.

GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.

Introduction to the ISBT 128 Labelling Standard for Blood Components.

EAE Training PROTOCOL SPECIFIC Objectives  Definitions  Assessment of Adverse Events  EAE Reporting.

Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,

CTCAE v3.0 Revision Project Working Group Information for Getting Started Prepared by: Ann Setser, BSN, MEd NCI Center for Bioinformatics July 11, 2008.

Methods We employ the UMLS Metathesaurus to annotate ICD-9 codes to MedDRA preferred terms (PTs) using the three-step process below. The mapping was applied.

CTCAE v3.0 Revision Project Draft 2 Tasks Steering Committee Centra/Teleconference Prepared by Ann Setser October 22, 2008.

CTCAE v3.0 Revision Project Draft 2 Tasks – Nov. – Dec Working Group Centra/Teleconference Prepared by Ann Setser Nov. 3, 2008.

GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.

[Name of Presenter] [Details of patient e.g. initials, hospital number etc.] [Date of meeting]

BiomedGT Wiki support for CTCAE update/ Creating a pre-coordinated OWL file Sherri de Coronado NCI CBIIT/ EVS May 1, 2009.

MedDRA® is a registered trademark of the International Federation

Keystone Heart Reflect Neurology

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.

FHIR Adverse Event Resource

5. National and international reporting of adverse events: mechanisms, routes and resources Multi-partner training package on active TB drug safety monitoring.

Assessing expectedness of an adverse event

DIA Clinical Safety and Pharmacovigilance Community

Safety Reporting Nichol McBee, MPH, CCRP.

Remote Monitoring of Adverse Events

Copenhagen University Hospital Rigshospitalet, Denmark

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

Pharmacovigilance in clinical trials

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Remote Monitoring of Adverse Events

SERIOUS ADVERSE EVENTS REPORTING

Human Gene Therapy Institutional Review Procedures

Model Enhanced Classification of Serious Adverse Events

Adverse Event Reporting _____________________________

Dr Tim England TICH-2 SAE adjudicator

Serious Adverse Event Reconciliation

Presentation transcript:

Alice Chen, MD, FACP Investigational Drug Branch, CTEP, DCTD National Cancer Institute CTCAE Version 4

CTCAE v3.0 Issues & MedDRA CTCAE v3.0 Terms –Multiple concepts –One/many element of Grade description is critical AE concept –Not all MedDRA terms 72% CTCAE = mapped to a single MedDRA term/code 28% CTCAE = CTEP-only code (with meaning to no one outside CTEP)

CTCAE Revision Status Phase 1: – Represent terms as single concept – MedDRA terms – Address CTCAE v3.0 Terms only Phase 2: Address Grading (severity) scales Add new terms (Working with MedDRA) – CTEP Help Desk Requests; Others – Definitions for terms – caBIG VCDE conformity Public Review: Phase 3: – Working Group; Steering Committee; Advisory Board Review Final: May 27 - Publication

General Characteristics of Grading Scale Grade 0No AE or within normal limits. Grade 1Mild AE (minor; no specific medical intervention; asymptomatic laboratory findings only, radiographic findings only; marginal clinical relevance) Grade 2Moderate AE (minimal intervention; local intervention; noninvasive intervention [packing, cautery] indicated); AE limiting instrumental ADL (e.g., shopping, laundry, transportation, ability to conduct finances).

General Characteristics of Grading Scale Severe AE (medically significant but not life-threatening). AEs in which initial inpatient hospitalization or prolongation of existing hospitalization is indicated; that are important medical events that may not be immediately life- threatening; that do not result in death. that do not result in hospitalization but may jeopardize the patient or may require intervention either to prevent hospitalization or to prevent the AE from becoming life-threatening or potentially resulting in death. that are disabling (result in persistent or significant disability or incapacity). Limit performance of basic activities of self care (getting in and out of bed, dressing, eating, getting around inside, bathing, or using the toilet). Grade 3

General Characteristics of Grading Scale Grade 4Life-threatening AE (the patient is at risk of death at the time of the event if immediate intervention is not undertaken) Grade 5Fatal Adverse Event

AE Terms: Draft 1 Single concept MedDRA terms that are common in oncology practice ~66% of CTCAE v3.0 terms appear in Draft 1 exactly as mapped to MedDRA ~33% of CTCAE v3.0 terms have been deleted –Infection with/without/with unknown ANC + site- specific infections ~70 New terms Remainder = Edits

INFECTION CATEGORY Infection with unknown ANC – Conjunctiva –MedDRA: Conjunctivitis infective Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) – Conjunctiva Infection with normal ANC or Grade 1 or 2 neutrophils - Conjunctiva CTEP - only codes

Comparison CTCAE v3.0 to Draft 1 CTCAE v3.0Draft 1 Broad Grouping of TermsCATEGORYSOC AE TermsMultiple concepts; non- MedDRA Single concept MedDRA Number of Terms1,059~800 Grading Scale0 – Other Components Short NameYesNo Also ConsiderYesTBD Navigation NoteYesTBD Representation as a Formal Vocabulary NoYes DefinitionsNoYes Formal Ongoing Governance NoYes

Summary CTCAE v4.0 All AEs are MedDRA LLT terms that are common in oncology practice AE Terms will be organized by Primary SOC Grading scales CTCAE v4.0 DRAFT posted for public review / comment March 23 – April 10, 2009 Listed on the CTEP website CTCAE v4.0 publication May 27, 2009 Long term Governance being established